Trial · NCT05487755
Investigational and Comparative Study in the Management of Diabetic Nephropathy
NCT05487755, Phase 3, Completed, Tanta University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Investigational and Comparative Study in the Management of Diabetic Nephropathy. Trials, record NCT05487755. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05487755
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Investigational and Comparative Study in the Management of Diabetic Nephropathy
- NCT number
- NCT05487755
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 90 participants, actual
- Lead sponsor
- Tanta University
- Conditions
- Diabetic Nephropathy Type 2
- Interventions
- Tadalafil 20Mg Oral Tablet, Pentoxifylline 400 MG Oral Tablet
- First posted
- 2022-08-04
- Last updated
- 2024-05-14
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Urinary albumin/creatinine ratio (ACR) | Change between baseline and six months after | Measurement of urine albumin to creatinne ratio by measurement of urine albumin using Turbidimetric immunoassay method and measurement of urine creatinnie by standard by enzymatic colorimetric methods |
| Primary | Change in Hemoglobin A1c (HbA1c). | Change between baseline and six months after | Measurement of Hemoglobin A1C using (HPLC: ion exchange chromatography) |
| Primary | Change in Fasting blood glucose. | Change between baseline and six months after | Measurement of Fasting blood glucose by using standard enzymatic colorimetric methods |
| Primary | Change in Sr Cr | Change between baseline and six months after | Measurement of serum creatinine using colorimetric technique |
| Primary | Change in Creatinine clearance | Change between baseline and six months after | Creatinine clearance was calculated by (Cockcroft-Gault Formula) |
| Primary | change in 2- Hours Postprandial blood glucose | Change between baseline and six months after | Measurement 2- Hours Postprandial blood glucose in blood using standard enzymatic colorimetric methods |
| Secondary | Change in serum ((TNF-α). | Change between baseline and six months after | Measurement of serum level of (TNF-α) by Enzyme linked immunosorbent assay (ELISA). |
| Secondary | Change in Urinary NGAL (uNGAL). | Change between baseline and six months after | Measurement of urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL)using by Enzyme linked immunosorbent assay ELISA technique: |
| Secondary | Change in Lipid profile (TG, LDL, and HDL). | Change between baseline and six months after | Measurement of serum lipid profile (TC,TG,HDL,LDL)using Enzymatic Colorimetric Method |
| Secondary | Change in serum malondialdehyde (MDA) . | Change between baseline and six months after | Meaurement of serum malondialdehyde by Enzyme linked immunosorbent assay (ELISA) . |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05487755
GET https://conductscience.org/api/trials/v1/NCT05487755/registered